)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Scancell Holdings
Scancell Holdings (SCLP) investor relations material
Scancell Holdings H2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2026 earnings summary9 Oct, 2026
Executive summary
Advanced melanoma Phase 3 trial of iSCIB1+ planned for Q4 2026, following FDA IND clearance and fast track designation and UK MHRA authorization.
Proposed Neuphoria merger and related financing could fund development plans, but completion depends on shareholder, regulatory and other conditions.
Financial highlights
FY2026 revenue was £nil vs £4.7m in FY2025; R&D expenses fell to £12.0m from £14.7m, mainly due to lower manufacturing costs.
Operating loss widened to £17.4m from £15.0m; net loss was £17.9m vs £12.3m, with no £1.8m convertible-note modification gain recorded in FY2026.
Cash and cash equivalents were £5.3m at 30 April 2026 vs £16.9m a year earlier; net cash used in operating activities was £10.8m.
Outlook and guidance
Phase 3 iSCIB1+ trial targeting ~550 patients with unresectable Stage IIIB or IV melanoma is expected to start in Q4 2026; further Phase 2 SCOPE PFS data expected in H1 2027.
A randomized neoadjuvant/adjuvant iSCIB1+ Phase 2 trial is intended for H1 2027, subject to financing and regulatory clearance.
Further ModiFY data for HNSCC and RCC are expected later in 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Scancell Holdings
- iSCIB1+ shows strong efficacy in advanced melanoma, with phase III and commercial expansion underway.SCLP
H.C. Wainwright 28th Annual Global Investment Conference - iSCIB1+ delivers robust efficacy in melanoma with a defined path to approval and major market potential.SCLPCorporate presentation
- Strong clinical progress and partnerships set up multiple value drivers and milestones for 2025.SCLPInvestor update
- SCOPE study advances with strong early results as GlyMab spinout drives strategic momentum.SCLPStatus update
- iSCIB1+ plus checkpoint inhibitors achieved 69% response and 69% PFS at 22 months in melanoma.SCLPStudy update
- iSCIB1+ achieved 74% PFS at 16 months, surpassing standard care and supporting phase III plans.SCLPStudy update
- Lead cancer vaccines deliver strong interim results; cash runway secured to H2 2026.SCLPH1 2025
- iSCIB1+ shows robust melanoma efficacy, supporting pipeline growth and solid cash runway.SCLPH2 2025
- iSCIB1+ achieved 74% PFS in melanoma; Phase 3 trial and key data readouts expected in 2026.SCLPH1 2026
Next Scancell Holdings earnings date
H1 202728 Jan, 2027
Scancell Holdings
Next Scancell Holdings earnings date
H1 202728 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)